Skip to content

Low Molecular Weight Heparin for the Prevention of Early TIPS Dysfunction

Post-TIPS Short-term Low Molecular Weight Heparin for the Prevention of Early TIPS Dysfunction

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03171727
Enrollment
117
Registered
2017-05-31
Start date
2017-06-01
Completion date
2019-12-30
Last updated
2019-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis, Portal Hypertension

Brief summary

Transjugular intrahepatic portosystemic shunt (TIPS) dysfunction is defined as a loss of decompression of the portal venous system due to occlusion or stenosis of the TIPS. Occlusion of the TIPS can either be due to thrombosis or hyperplasia of the intima. Thrombosis of the TIPS usually occurs early and can happen within 24 hours of TIPS creation. The frequency of this complication is on the order of 10%-15% when bare stents are used. Post-TIPS short-term low molecular weight heparin (LMWH) was used to prevent the early thrombosis formation. Weather post-TIPS LMWH was necessary when polytetrafluoroethylene-covered stent was used during TIPS creation was not answered. The present study was designed to evaluate the effect of short-term use of LMWH on early TIPS dysfunction.

Interventions

DRUGlow molecular weight heparin

After TIPS procedure was performed, low molecular weight heparin was given for three days.

Sponsors

West China Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Diagnosis of liver cirrhosis 2. Technical success of TIPS was achieved.

Exclusion criteria

1. Non-cirrhotic portal hypertension 2. Portal vein thrombosis 3. Budd-Chiari syndrome 4. Pregnancy 5. Contradictions to anticoagulation therapy

Design outcomes

Primary

MeasureTime frameDescription
TIPS patency rateone yearAnalysis

Secondary

MeasureTime frameDescription
LMWH-related complicationone monthAnalysis
Mortality rateone yearAnalysis

Countries

China

Contacts

Primary Contactxuefeng luo
luo_xuefeng@yeah.net02885422311

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026